MX2015015966A - Compuestos para la modulacion de cinasas e indicaciones para los mismos. - Google Patents
Compuestos para la modulacion de cinasas e indicaciones para los mismos.Info
- Publication number
- MX2015015966A MX2015015966A MX2015015966A MX2015015966A MX2015015966A MX 2015015966 A MX2015015966 A MX 2015015966A MX 2015015966 A MX2015015966 A MX 2015015966A MX 2015015966 A MX2015015966 A MX 2015015966A MX 2015015966 A MX2015015966 A MX 2015015966A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- kinase modulation
- indications therefor
- methods
- indications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Se describen compuestos activos sobre proteína cinasas y métodos para regular rutas de proteína cinasas, así como métodos para utilizar tales compuestos para tratar enfermedades y padecimientos asociados con la actividad aberrante de las proteína cinasas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361829190P | 2013-05-30 | 2013-05-30 | |
PCT/US2014/040076 WO2014194127A1 (en) | 2013-05-30 | 2014-05-29 | Compounds for kinase modulation, and indications therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015015966A true MX2015015966A (es) | 2016-04-13 |
Family
ID=51023140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015015966A MX2015015966A (es) | 2013-05-30 | 2014-05-29 | Compuestos para la modulacion de cinasas e indicaciones para los mismos. |
Country Status (18)
Country | Link |
---|---|
US (2) | US9873700B2 (es) |
EP (1) | EP3004060B1 (es) |
JP (1) | JP2016520131A (es) |
KR (1) | KR20160013028A (es) |
CN (1) | CN105228983A (es) |
AR (1) | AR096450A1 (es) |
AU (1) | AU2014274093B2 (es) |
BR (1) | BR112015028845A2 (es) |
CA (1) | CA2912568A1 (es) |
HK (1) | HK1219732A1 (es) |
IL (1) | IL242587A0 (es) |
MX (1) | MX2015015966A (es) |
PH (1) | PH12015502610A1 (es) |
RU (1) | RU2015149937A (es) |
SG (1) | SG11201509338QA (es) |
TW (1) | TW201533028A (es) |
UY (1) | UY35596A (es) |
WO (1) | WO2014194127A1 (es) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
BR112012011792A2 (pt) | 2009-11-18 | 2015-10-13 | Plexxikon Inc | "compostos e métodos para modulação de quinases, e indicações para os mesmos" |
RU2012131373A (ru) | 2009-12-23 | 2014-01-27 | Плексксикон, Инк. | Соединения и способы модулирования киназы, а также показания для такого модулирования |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
MY162950A (en) | 2011-02-07 | 2017-07-31 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
RU2631487C2 (ru) | 2011-05-17 | 2017-09-22 | Плексксикон Инк. | Модуляция киназ и показания к её применению |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
RU2637948C2 (ru) * | 2012-05-03 | 2017-12-08 | Дженентек, Инк. | Производные пиразоламинопиримидина в качестве модуляторов обогащенной лейциновыми повторами киназы 2 (lrrk2) для применения при лечении болезни паркинсона |
US9150570B2 (en) * | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
ES2889757T3 (es) | 2012-09-06 | 2022-01-13 | Plexxikon Inc | Compuestos y procedimientos para la modulación de quinasas e indicaciones para estos |
NZ711896A (en) | 2012-12-21 | 2018-04-27 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
AU2014233437B2 (en) | 2013-03-15 | 2018-07-26 | Opna Immuno Oncology, SA | Heterocyclic compounds and uses thereof |
KR20160013028A (ko) | 2013-05-30 | 2016-02-03 | 플렉시콘, 인코퍼레이티드 | 키나제 조정을 위한 화합물 및 그에 대한 적응증 |
WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
CA2961356C (en) | 2014-09-15 | 2023-03-07 | Plexxikon Inc. | Heterocyclic compounds and their uses in modulating bromodomain and for treating diseases or conditions relevant thereto |
ES2789331T3 (es) * | 2015-03-02 | 2020-10-26 | Rigel Pharmaceuticals Inc | Inhibidores de TGF-beta |
WO2016164641A1 (en) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
CN104829613B (zh) * | 2015-04-13 | 2020-06-09 | 赤峰蒙广生物科技有限公司 | 二芳基取代的吡唑并环类衍生物、其制备方法及其在医药领域的应用 |
HUE050506T2 (hu) | 2015-05-06 | 2020-12-28 | Plexxikon Inc | Kinázokat moduláló vegyület szilárd formái |
ES2774178T3 (es) | 2015-05-06 | 2020-07-17 | Plexxikon Inc | Síntesis de derivados de 1h-pirrolo[2,3-B] piridina que modulan cinasas |
US9814714B2 (en) | 2015-05-22 | 2017-11-14 | Plexxikon Inc. | Kinase modulation, and indications therefor |
WO2016191303A1 (en) * | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
KR20180041135A (ko) | 2015-07-16 | 2018-04-23 | 어레이 바이오파마 인크. | Ret 키나아제 억제제로서 치환된 피라졸로[1,5-a]피리딘 화합물 |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
MX2018003432A (es) | 2015-09-21 | 2018-06-08 | Plexxikon Inc | Compuestos heterociclicos y usos de los mismos. |
EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
MX2018006856A (es) | 2015-12-07 | 2018-08-01 | Plexxikon Inc | Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos. |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
EP3430005B1 (en) | 2016-03-16 | 2021-12-08 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
TN2018000338A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Methods of treating pediatric cancers |
BR112018070304A2 (pt) | 2016-04-04 | 2019-01-29 | Loxo Oncology Inc | formulações líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
BR112018073504A2 (pt) | 2016-05-18 | 2019-03-26 | Array Biopharma, Inc. | processo para preparar (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazol[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida e sais da mesma |
MX2018016419A (es) * | 2016-06-21 | 2019-09-09 | Nerviano Medical Sciences Srl | Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida. |
CN107722013B (zh) * | 2016-08-11 | 2021-01-12 | 中国科学院上海药物研究所 | 去氮嘌呤类化合物及其药物组合物、制备方法和用途 |
KR20190035925A (ko) | 2016-08-24 | 2019-04-03 | 아르퀼 인코포레이티드 | 아미노-피롤로피리미디논 화합물 및 이의 사용 방법 |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
EP3515909A1 (en) | 2016-09-23 | 2019-07-31 | Cellipse | Lim kinase inhibitors, pharmaceutical composition and method of use in limk-mediated diseases |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JP7193460B2 (ja) | 2016-12-23 | 2022-12-20 | プレキシコン インコーポレーテッド | Cdk8調節およびその適応症のための化合物および方法 |
JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
WO2018175311A1 (en) | 2017-03-20 | 2018-09-27 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
CA3070505C (en) | 2017-07-25 | 2023-09-26 | Plexxikon Inc. | Formulations of a compound modulating kinases |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
JP2020536917A (ja) | 2017-10-13 | 2020-12-17 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節するための化合物の固体形態 |
CN112165958A (zh) | 2017-10-27 | 2021-01-01 | 普莱希科公司 | 调制激酶的化合物的制剂 |
JP7061195B2 (ja) | 2018-01-18 | 2022-04-27 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[3,4-d]ピリミジン化合物 |
WO2019142128A1 (en) * | 2018-01-18 | 2019-07-25 | Integral Biosciences Private Limited | Dual inhibitors of alk5 and p38α map kinase |
JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Retキナーゼ阻害剤としての置換ピラゾリル[4,3-c]ピリジン化合物 |
CA3087354C (en) | 2018-01-18 | 2023-01-03 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
CA3089678A1 (en) | 2018-01-31 | 2019-08-08 | Heparegenix Gmbh | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
JP2021518367A (ja) | 2018-03-20 | 2021-08-02 | プレキシコン インコーポレーテッドPlexxikon Inc. | Idoおよびtdo調節のための化合物および方法、ならびにそれらのための兆候 |
EP3810139A1 (en) | 2018-06-21 | 2021-04-28 | HepaRegeniX GmbH | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
MX2020014102A (es) | 2018-07-16 | 2021-05-27 | Heparegenix Gmbh | Inhibidores de proteina quinasa para promover la regeneracion del higado o reducir o prevenir la muerte de hepatocito. |
CA3224949A1 (en) | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
EP3842439A4 (en) | 2018-08-21 | 2022-04-27 | Kyorin Pharmaceutical Co., Ltd. | BICYCLIC HETEROAROMATIC RING DERIVATIVE |
ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
WO2020124397A1 (en) * | 2018-12-19 | 2020-06-25 | Inventisbio Shanghai Ltd. | C-terminal src kinase inhibitors |
US20220081438A1 (en) | 2018-12-19 | 2022-03-17 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
JP2022515197A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | がんを治療するためのfgfr阻害剤としての7-((3,5-ジメトキシフェニル)アミノ)キノキサリン誘導体 |
CN113710668A (zh) | 2019-04-09 | 2021-11-26 | 普莱希科公司 | 用于ep300或cbp调节及其适应症的缩合吖嗪 |
AU2020283597A1 (en) * | 2019-05-31 | 2021-11-25 | Fochon Biosciences, Ltd. | Substituted pyrrolo (2, 3-b) pyridine and pyrazolo (3, 4-b) pyridine derivatives as protein kinase inhibitors |
BR112022000325A2 (pt) | 2019-07-11 | 2022-03-15 | Escape Bio Inc | Indazois e azaindazois como inibidores de lrrk2 |
AU2020320001A1 (en) | 2019-07-29 | 2022-03-10 | Heparegenix Gmbh | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
IL294214A (en) | 2019-12-27 | 2022-08-01 | Schr?Dinger Inc | Cyclic compounds and methods of using them |
EP4090659A1 (en) | 2020-01-15 | 2022-11-23 | HepaRegeniX GmbH | 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases |
AU2021261383A1 (en) | 2020-04-23 | 2022-11-17 | Opna Bio SA | Compounds and methods for CD73 modulation and indications therefor |
WO2022036176A1 (en) * | 2020-08-13 | 2022-02-17 | Albert Einstein College Of Medicine | N-cyclyl-sulfonamides useful for inhibiting raf |
US11628176B2 (en) | 2020-08-21 | 2023-04-18 | Opna Bio SA | Combinational drug therapies |
US20230365584A1 (en) | 2020-09-10 | 2023-11-16 | Schrödinger, Inc. | Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer |
EP4284804A1 (en) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
CN113018415B (zh) * | 2021-03-17 | 2022-07-01 | 遵义医科大学 | 一种药物组合及其应用 |
TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
AU2022290823A1 (en) * | 2021-06-09 | 2023-12-07 | F. Hoffmann-La Roche Ag | New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide |
CN113941001B (zh) * | 2021-12-09 | 2023-09-08 | 宁夏医科大学 | Craf抑制剂在制备抗肿瘤的药物中的应用 |
WO2023213965A1 (en) * | 2022-05-05 | 2023-11-09 | University Of Dundee | Inhibitors of cdk8 and cdk19 |
WO2023240024A1 (en) * | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040171062A1 (en) | 2002-02-28 | 2004-09-02 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
PT2277551E (pt) | 2002-09-06 | 2013-08-22 | Cerulean Pharma Inc | Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente |
WO2004024895A2 (en) | 2002-09-16 | 2004-03-25 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
US20050048573A1 (en) | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
US20050170431A1 (en) | 2003-02-28 | 2005-08-04 | Plexxikon, Inc. | PYK2 crystal structure and uses |
US20050079548A1 (en) | 2003-07-07 | 2005-04-14 | Plexxikon, Inc. | Ligand development using PDE4B crystal structures |
EP1648867B1 (en) | 2003-07-17 | 2013-09-04 | Plexxikon Inc. | Ppar active compounds |
US7348338B2 (en) | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
US20050164300A1 (en) | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
US7517970B2 (en) | 2003-12-19 | 2009-04-14 | Plexxikon, Inc. | Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same |
US20070066641A1 (en) | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
EP1696920B8 (en) | 2003-12-19 | 2015-05-06 | Plexxikon Inc. | Compounds and methods for development of ret modulators |
CN101031293A (zh) | 2004-05-06 | 2007-09-05 | 普莱希科公司 | Pde4b抑制剂及其应用 |
JP2008503473A (ja) | 2004-06-17 | 2008-02-07 | プレキシコン,インコーポレーテッド | C−kit活性を調節する化合物 |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
CA2583428A1 (en) | 2004-09-03 | 2006-03-09 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
EP1819673A2 (en) | 2004-11-30 | 2007-08-22 | Plexxikon, Inc. | Indole derivatives for use as ppar active compounds |
WO2006060535A2 (en) | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Indole derivatives for use as ppar active compounds |
US20060160135A1 (en) | 2004-12-08 | 2006-07-20 | Weiru Wang | SF-1 and LRH-1 modulator development |
MX2007014377A (es) | 2005-05-17 | 2008-02-06 | Plexxikon Inc | Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina. |
TWI522337B (zh) | 2005-06-22 | 2016-02-21 | 普雷辛肯公司 | 用於激酶調節的化合物及方法及其適應症 |
SG165362A1 (en) | 2005-09-07 | 2010-10-28 | Plexxikon Inc | Ppar active compounds |
US20080234349A1 (en) | 2005-09-07 | 2008-09-25 | Jack Lin | PPAR active compounds |
CA2621406A1 (en) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | Pparactive compounds |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
CN101641351A (zh) | 2006-12-21 | 2010-02-03 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
PE20090159A1 (es) | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
RU2009137190A (ru) | 2007-03-08 | 2011-04-20 | Плексксикон, Инк. (Us) | Соединения, обладающие активностью в отношении ppar |
SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US8394795B2 (en) | 2008-02-29 | 2013-03-12 | Array Biopharma Inc. | Pyrazole [3, 4-B] pyridine Raf inhibitors |
WO2009111278A2 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009152083A1 (en) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | 5h-pyrr0l0 [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor |
US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
PE20120184A1 (es) | 2009-03-11 | 2012-03-28 | Plexxikon Inc | Derivados del pirrolo[2,3-b]piridina para la inhibicion de las proteinas quinasas raf |
AU2010224184A1 (en) | 2009-03-11 | 2011-09-29 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of Raf kinases |
WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
MX349923B (es) | 2009-04-03 | 2017-08-21 | Hoffmann La Roche | Composiciones del ácido propano-1-sulfónico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil]-amida y el uso de las mismas. |
SG175877A1 (en) | 2009-05-04 | 2011-12-29 | Plexxikon Inc | Compounds and methods for inhibition of renin, and indications therefor |
TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
CN102482283A (zh) | 2009-08-28 | 2012-05-30 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
JP2013503188A (ja) * | 2009-08-28 | 2013-01-31 | アレイ バイオファーマ、インコーポレイテッド | Raf阻害化合物およびその使用方法 |
AR077975A1 (es) * | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
US8242260B2 (en) * | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
SG178899A1 (en) * | 2009-08-28 | 2012-04-27 | Array Biopharma Inc | Raf inhibitor compounds and methods of use thereof |
ES2633317T3 (es) | 2009-11-06 | 2017-09-20 | Plexxikon, Inc. | Compuestos y métodos para la modulación de quinasas, e indicaciones para ello |
EP2498608A4 (en) * | 2009-11-10 | 2013-04-24 | Glaxosmithkline Llc | BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS |
BR112012011792A2 (pt) | 2009-11-18 | 2015-10-13 | Plexxikon Inc | "compostos e métodos para modulação de quinases, e indicações para os mesmos" |
RU2012131373A (ru) | 2009-12-23 | 2014-01-27 | Плексксикон, Инк. | Соединения и способы модулирования киназы, а также показания для такого модулирования |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
US8642606B2 (en) | 2010-09-29 | 2014-02-04 | Plexxikon Inc. | ZAP-70 active compounds |
MY162950A (en) | 2011-02-07 | 2017-07-31 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
RU2631487C2 (ru) | 2011-05-17 | 2017-09-22 | Плексксикон Инк. | Модуляция киназ и показания к её применению |
US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
ES2889757T3 (es) * | 2012-09-06 | 2022-01-13 | Plexxikon Inc | Compuestos y procedimientos para la modulación de quinasas e indicaciones para estos |
NZ711896A (en) | 2012-12-21 | 2018-04-27 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
AU2014233437B2 (en) | 2013-03-15 | 2018-07-26 | Opna Immuno Oncology, SA | Heterocyclic compounds and uses thereof |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
KR20160013028A (ko) | 2013-05-30 | 2016-02-03 | 플렉시콘, 인코퍼레이티드 | 키나제 조정을 위한 화합물 및 그에 대한 적응증 |
WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
CA2961356C (en) | 2014-09-15 | 2023-03-07 | Plexxikon Inc. | Heterocyclic compounds and their uses in modulating bromodomain and for treating diseases or conditions relevant thereto |
WO2016164641A1 (en) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
HUE050506T2 (hu) | 2015-05-06 | 2020-12-28 | Plexxikon Inc | Kinázokat moduláló vegyület szilárd formái |
ES2774178T3 (es) | 2015-05-06 | 2020-07-17 | Plexxikon Inc | Síntesis de derivados de 1h-pirrolo[2,3-B] piridina que modulan cinasas |
WO2016191303A1 (en) | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
US9814714B2 (en) | 2015-05-22 | 2017-11-14 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
MX2018003432A (es) | 2015-09-21 | 2018-06-08 | Plexxikon Inc | Compuestos heterociclicos y usos de los mismos. |
MX2018006856A (es) | 2015-12-07 | 2018-08-01 | Plexxikon Inc | Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos. |
EP3430005B1 (en) | 2016-03-16 | 2021-12-08 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
JP7193460B2 (ja) | 2016-12-23 | 2022-12-20 | プレキシコン インコーポレーテッド | Cdk8調節およびその適応症のための化合物および方法 |
WO2018175311A1 (en) | 2017-03-20 | 2018-09-27 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
-
2014
- 2014-05-29 KR KR1020157033201A patent/KR20160013028A/ko not_active Application Discontinuation
- 2014-05-29 BR BR112015028845A patent/BR112015028845A2/pt not_active IP Right Cessation
- 2014-05-29 CN CN201480029525.6A patent/CN105228983A/zh active Pending
- 2014-05-29 WO PCT/US2014/040076 patent/WO2014194127A1/en active Application Filing
- 2014-05-29 CA CA2912568A patent/CA2912568A1/en not_active Abandoned
- 2014-05-29 TW TW103118934A patent/TW201533028A/zh unknown
- 2014-05-29 EP EP14733877.6A patent/EP3004060B1/en active Active
- 2014-05-29 US US14/290,786 patent/US9873700B2/en active Active
- 2014-05-29 RU RU2015149937A patent/RU2015149937A/ru unknown
- 2014-05-29 AU AU2014274093A patent/AU2014274093B2/en not_active Ceased
- 2014-05-29 MX MX2015015966A patent/MX2015015966A/es unknown
- 2014-05-29 JP JP2016516830A patent/JP2016520131A/ja active Pending
- 2014-05-29 SG SG11201509338QA patent/SG11201509338QA/en unknown
- 2014-05-30 AR ARP140102152A patent/AR096450A1/es unknown
- 2014-05-30 UY UY0001035596A patent/UY35596A/es not_active Application Discontinuation
-
2015
- 2015-11-12 IL IL242587A patent/IL242587A0/en unknown
- 2015-11-23 PH PH12015502610A patent/PH12015502610A1/en unknown
-
2016
- 2016-07-04 HK HK16107741.9A patent/HK1219732A1/zh unknown
-
2017
- 2017-12-11 US US15/838,268 patent/US10421761B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20160013028A (ko) | 2016-02-03 |
BR112015028845A2 (pt) | 2017-07-25 |
US9873700B2 (en) | 2018-01-23 |
US10421761B2 (en) | 2019-09-24 |
PH12015502610A1 (en) | 2016-02-29 |
AU2014274093A1 (en) | 2015-12-03 |
HK1219732A1 (zh) | 2017-04-13 |
WO2014194127A1 (en) | 2014-12-04 |
SG11201509338QA (en) | 2015-12-30 |
EP3004060B1 (en) | 2019-11-27 |
EP3004060A1 (en) | 2016-04-13 |
AR096450A1 (es) | 2015-12-30 |
CN105228983A (zh) | 2016-01-06 |
JP2016520131A (ja) | 2016-07-11 |
US20140357612A1 (en) | 2014-12-04 |
TW201533028A (zh) | 2015-09-01 |
AU2014274093B2 (en) | 2018-11-08 |
US20180099975A1 (en) | 2018-04-12 |
UY35596A (es) | 2014-12-31 |
IL242587A0 (en) | 2016-02-01 |
RU2015149937A (ru) | 2017-07-06 |
CA2912568A1 (en) | 2014-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502610A1 (en) | Compounds for kinase modulation, and indications therefor | |
MX358128B (es) | Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos. | |
PH12015501370B1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
WO2014039714A3 (en) | Compounds and methods for kinase modulation, and indications therefor | |
AU2018236800B2 (en) | DNA-PK inhibitors | |
PH12016500582A1 (en) | Heterocyclic compounds and uses thereof | |
CO2017005217A2 (es) | Derivados de tieno[2,3-c]pyrrol-4-ona como inhibidores de erk | |
EA201491721A1 (ru) | Соединения и способы модуляции киназ и показания для их применения | |
MY148468A (en) | Compounds and methods for kinase modulation, and indications therefor | |
MX2009006688A (es) | Compuestos y metodos para modulacion de cinasas, e indicaciones para ello. | |
MX2021013118A (es) | Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton. | |
UY35798A (es) | Inhibidores del receptor del factor de crecimiento de fibroblastos | |
MX369472B (es) | Inhibidores del receptor del factor de crecimiento de fibroblastos. | |
JOP20120246B1 (ar) | مركبات و تركيبات كمثبطات كيناز c-Kit | |
PH12014502513A1 (en) | Nampt inhibitors | |
GEP20166489B (en) | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors | |
NZ740817A (en) | Pcna inhibitors | |
MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. | |
MX2018007361A (es) | Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas. | |
BR112018008931A8 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
EA201390519A1 (ru) | Замещенные соединения пиридазинкарбоксамида в качестве киназных ингибиторов | |
WO2014152917A3 (en) | Physiological ligands for gpr139 | |
NZ779756A (en) | Pcna inhibitors | |
NZ750581A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
UA107743C2 (ru) | Способ лечения аденокарциномы |